Skip to main content

Table 2 PTEN pathway protein levels across groups and by ASD and PTEN status

From: Cross-level analysis of molecular and neurobehavioral function in a prospective series of patients with germline heterozygous PTEN mutations with and without autism

 

(1) Macro-ASD

(2) PTEN no-ASD

(3) PTEN-ASD

F (p)

R2

ASD

PTEN

M (SD) n = 20

M (SD) n = 16

M (SD) n = 25

β (p)

β (p)

PTEN

140.5 (41.7)

121.1 (50.8)

116.4 (47.4)

1.59 (.213)

.05

 − .04 (.754)

 − .24 (.045)

P- AKT

115.3 (42.0)

126.5 (36.2)

122.1 (38.5)

0.38 (.686)

.01

 − .05 (.722)

.08 (.568)

Total AKT

133.4 (75.3)

139.1 (64.3)

126.3 (64.9)

0.18 (.838)

.01

 − .08 (.561)

 − .05 (.730)

P- ERK

110.0 (57.0)

130.0 (67.8)

105.3 (54.2)

0.90 (.411)

.03

 − .19 (.196)

 − .04 (.790)

Total ERK

195.4 (79.5)

194.5 (70.1)

183.9 (72.5)

0.17 (.847)

.01

 − .06 (.657)

 − .08 (.606)

IGFBP2

166.1 (41.3)

180.4 (41.7)

156.5 (54.4)

1.25 (.295)

.04

.22 (.120)

 − .69 (.498)

MnSOD

175.5 (48.9)

202.2 (41.0)

160.5 (46.9)

4.00 (.024)

.12

 − .38 (.006)

 − .15 (.284)

P- S6

94.6 (58.6)

67.1 (33.8)

115.5 (59.3)

3.54 (.035)

.11

.36 (.010)

.17 (.226)

S6

160.4 (47.6)

145.2 (52.0)

131.7 (43.4)

2.07 (.136)

.07

 − .13 (.373)

 − .28 (.047)

EIF2A

17.8 (5.1)

19.9 (4.1)

19.9 (4.5)

1.54 (.222)

.05

 − .01 (.962)

.22 (.120)

p27

13.7 (5.7)

16.4 (6.6)

12.8 (7.4)

1.43 (.248)

.05

 − .24 (.100)

 − .07 (.649)

P-AKT/AKT

1.22 (1.11)

1.17 (0.84)

1.22 (0.64)

0.02 (.978)

 < .01

.05 (.848)

 < .01 (.999)

P-ERK/ERK

0.87 (0.95)

0.91 (0.90)

0.80 (0.69)

0.10 (.903)

 < .01

 − .12 (.666)

 − .08 (.770)

P-S6/S6

0.64 (0.44)

0.52 (0.27)

0.88 (0.42)

4.40 (.017)

.13

.36 (.007)

.24 (.045)

  1. All protein levels are 10-e + 3. Bold designates p < .05, and italics designates p ≤ .10. Per a priori hypothesis, a one-tailed p value was used for evaluating the effect of PTEN mutations status on PTEN protein levels